| (CCTG) OVC.2 / NRG-GY005 | A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) | Hirte, Dr Hal | Open to recruitment | NCT02502266 |
| (Clovis) CO-338-087 / GOG-3020 / ENGOT-ov45/NCRI/ATHENA | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy | Elit, Dr Laurie | Open to recruitment | NCT03522246 |
| (Merck) MK-7902-001 / E7080-G000-313 / LEAP-001 | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma | Hirte, Dr Hal | Open to recruitment | NCT03884101 |
| (Tesaro) 3000-03-005 / ENGOT-OV44 / FIRST | A Patient Centric Randomized Phase 3 Comparison of Standard of Care Platinum Based Therapy to the Same Plus TSR-042 As First Line Treatment of Patients with Stage III or IV Non-Mucinous Ovarian Cancer. | Hirte, Dr Hal | Open to recruitment | NCT03602859 |
| (UHN) BioDIVA | Biomarker Discovery Project in High Grade Serous Ovarian Cancer | Elit, Dr Laurie | Open to recruitment | NCT03419689 |
Find a Trial
Contact Us